Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. more
Time Frame | SWTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.84% | -2.27% | -0.57% |
1-Month Return | 10.34% | -3.96% | 1.21% |
3-Month Return | 2.35% | -9.7% | 7.57% |
6-Month Return | -2.15% | -3.37% | 11.45% |
1-Year Return | 10.82% | 3.71% | 28.48% |
3-Year Return | -45.3% | 3.8% | 29.52% |
5-Year Return | 32.53% | 39.78% | 90.66% |
10-Year Return | 69.24% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 35.00M | 35.00M | 6.15M | 5.45M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.56,"profit":true},{"date":"2023-12-31","value":15.56,"profit":true}] |
Cost of Revenue | 192.00K | 349.00K | 490.00K | 1.90M | 422.00K | [{"date":"2019-12-31","value":10.13,"profit":true},{"date":"2020-12-31","value":18.41,"profit":true},{"date":"2021-12-31","value":25.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.26,"profit":true}] |
Gross Profit | (192.00K) | 34.65M | (490.00K) | 6.15M | 5.03M | [{"date":"2019-12-31","value":-0.55,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1.41,"profit":false},{"date":"2022-12-31","value":17.74,"profit":true},{"date":"2023-12-31","value":14.5,"profit":true}] |
Gross Margin | - | 99.00% | (1.40%) | 100.00% | 92.25% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":99,"profit":true},{"date":"2021-12-31","value":-1.4,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.25,"profit":true}] |
Operating Expenses | 59.24M | 81.32M | 173.47M | 280.67M | 348.04M | [{"date":"2019-12-31","value":17.02,"profit":true},{"date":"2020-12-31","value":23.37,"profit":true},{"date":"2021-12-31","value":49.84,"profit":true},{"date":"2022-12-31","value":80.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (59.24M) | (46.32M) | (173.47M) | (280.67M) | (343.01M) | [{"date":"2019-12-31","value":-5923900000,"profit":false},{"date":"2020-12-31","value":-4632400000,"profit":false},{"date":"2021-12-31","value":-17346800000,"profit":false},{"date":"2022-12-31","value":-28067400000,"profit":false},{"date":"2023-12-31","value":-34301300000,"profit":false}] |
Total Non-Operating Income/Expense | 4.48M | 2.08M | 256.00K | 9.54M | 40.06M | [{"date":"2019-12-31","value":11.18,"profit":true},{"date":"2020-12-31","value":5.19,"profit":true},{"date":"2021-12-31","value":0.64,"profit":true},{"date":"2022-12-31","value":23.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (58.31M) | (45.57M) | (173.91M) | (277.42M) | (325.10M) | [{"date":"2019-12-31","value":-5830600000,"profit":false},{"date":"2020-12-31","value":-4557400000,"profit":false},{"date":"2021-12-31","value":-17391000000,"profit":false},{"date":"2022-12-31","value":-27741700000,"profit":false},{"date":"2023-12-31","value":-32510400000,"profit":false}] |
Income Taxes | (3.55M) | (1.33M) | (698.00K) | (3.26M) | (22.95M) | [{"date":"2019-12-31","value":-354700000,"profit":false},{"date":"2020-12-31","value":-133000000,"profit":false},{"date":"2021-12-31","value":-69800000,"profit":false},{"date":"2022-12-31","value":-325700000,"profit":false},{"date":"2023-12-31","value":-2294700000,"profit":false}] |
Income After Taxes | (54.76M) | (44.24M) | (173.21M) | (274.16M) | (302.16M) | [{"date":"2019-12-31","value":-5475900000,"profit":false},{"date":"2020-12-31","value":-4424400000,"profit":false},{"date":"2021-12-31","value":-17321200000,"profit":false},{"date":"2022-12-31","value":-27416000000,"profit":false},{"date":"2023-12-31","value":-30215700000,"profit":false}] |
Income From Continuous Operations | (58.31M) | (45.57M) | (173.91M) | (277.42M) | (304.96M) | [{"date":"2019-12-31","value":-5830600000,"profit":false},{"date":"2020-12-31","value":-4557400000,"profit":false},{"date":"2021-12-31","value":-17391000000,"profit":false},{"date":"2022-12-31","value":-27741700000,"profit":false},{"date":"2023-12-31","value":-30496000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (54.76M) | (44.24M) | (173.21M) | (274.16M) | (325.10M) | [{"date":"2019-12-31","value":-5475900000,"profit":false},{"date":"2020-12-31","value":-4424400000,"profit":false},{"date":"2021-12-31","value":-17321200000,"profit":false},{"date":"2022-12-31","value":-27416000000,"profit":false},{"date":"2023-12-31","value":-32510400000,"profit":false}] |
EPS (Diluted) | (2.59) | (1.05) | (3.58) | (5.21) | (5.15) | [{"date":"2019-12-31","value":-259,"profit":false},{"date":"2020-12-31","value":-105,"profit":false},{"date":"2021-12-31","value":-358,"profit":false},{"date":"2022-12-31","value":-521,"profit":false},{"date":"2023-12-31","value":-515,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SWTX | |
---|---|
Cash Ratio | 5.33 |
Current Ratio | 6.16 |
Quick Ratio | 6.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SWTX | |
---|---|
ROA (LTM) | -34.28% |
ROE (LTM) | -59.33% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SWTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SWTX | |
---|---|
Trailing PE | NM |
Forward PE | 322.58 |
P/S (TTM) | 21.82 |
P/B | 5.55 |
Price/FCF | NM |
EV/R | 19.10 |
EV/Ebitda | NM |
SpringWorks Therapeutics Inc (SWTX) share price today is $38.3
Yes, Indians can buy shares of SpringWorks Therapeutics Inc (SWTX) on Vested. To buy SpringWorks Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SWTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of SpringWorks Therapeutics Inc (SWTX) via the Vested app. You can start investing in SpringWorks Therapeutics Inc (SWTX) with a minimum investment of $1.
You can invest in shares of SpringWorks Therapeutics Inc (SWTX) via Vested in three simple steps:
The 52-week high price of SpringWorks Therapeutics Inc (SWTX) is $53.92. The 52-week low price of SpringWorks Therapeutics Inc (SWTX) is $28.21.
The price-to-earnings (P/E) ratio of SpringWorks Therapeutics Inc (SWTX) is
The price-to-book (P/B) ratio of SpringWorks Therapeutics Inc (SWTX) is 5.55
The dividend yield of SpringWorks Therapeutics Inc (SWTX) is 0.00%
The market capitalization of SpringWorks Therapeutics Inc (SWTX) is $2.96B
The stock symbol (or ticker) of SpringWorks Therapeutics Inc is SWTX